These data suggest that low-dose TSA only enhances the functional activity of tumor-infiltrating CD4+ T cells and CD8+ T cells but not that of draining lymph node resident T cells, suggesting that the immunostimulatory effect of low-dose TSA treatment was only limited to the TME. The gene discussed is CD8A; the disease is neoplasm.